# Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

> **NCT02959918** · PHASE2 · COMPLETED · sponsor: **Selecta Biosciences, Inc.** · enrollment: 152 (actual)

## Conditions studied

- Gout Chronic
- Hyperuricemia

## Interventions

- **DRUG:** SEL-212
- **DRUG:** SEL-037
- **DRUG:** SVP-rapamycin (SEL-110)

## Key facts

- **NCT ID:** NCT02959918
- **Lead sponsor:** Selecta Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10
- **Primary completion:** 2018-12
- **Final completion:** 2019-01
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959918, "Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02959918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*